Capricor Therapeutics Inc diskutieren
Capricor Therapeutics Inc
WKN: A2PLU4 / Name: Capricor / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
19,74 €
29,05 %
Duchenne-Muskeldystrophie Duchenne (DMD)
folgen
(Zielkurs erreicht)
$
| Biotechnologie | Vereinigte Staaten
$
(Vom Mitglied beendet)
(Vom Mitglied beendet)
Viel versprechende Daten CAP-1002
$
(Vom Mitglied beendet)
SecteurRecherche biotechnologique et médicale Agenda 15/11 Publication de résultats
Develops innovative products for the treatment of cardiovascular diseases
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions.
Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.
The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions.
Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.
The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
Nombre d'employés : 39 personnes
(Zielkurs erreicht)
Sell mit Kursziel 0,0
Sell beendet
Buy mit Kursziel 1,5
Buy Capricor Therapeutics Inc
Buy Capricor Therapeutics Inc
Sell Capricor Therapeutics Inc
Buy Capricor Therapeutics Inc
Sell mit Kursziel 1,0
Buy Capricor Therapeutics Inc
Sell mit Kursziel 1,0
Neueste Beiträge
Akuma in Biontech SE diskutieren, BioNTech SE ADR